Apellis Pharmaceuticals Inc (NAS:APLS)
$ 28.075 -0.485 (-1.7%) Market Cap: 3.49 Bil Enterprise Value: 3.59 Bil PE Ratio: 0 PB Ratio: 12.94 GF Score: 42/100

Apellis Pharmaceuticals Inc The Evolution of Complement Targeted Therapies Panel at Stifel Immunology & Inflammation Summit (Virtual) Transcript

Oct 01, 2020 / 01:00PM GMT
Release Date Price: $31.77 (+5.30%)
Derek Christian Archila
Stifel, Nicolaus & Company, Incorporated, Research Division - Director & Senior Analyst

Hey, good morning, everyone, and thanks for joining us for the first Annual Immunology and Inflammation Summit here at Stifel. I hope you're all doing well and staying safe.

So today, we're going to be assessing some of the hot topics in this therapeutic area. And we're kicking this event off today with our panel on complement-targeted therapies.

So with us today for the first panel this morning, we have Dr. Cedric Francois, the CEO of Apellis Pharmaceuticals. And then also, we have Grant Blouse, the Senior Vice President of Translational Research at Catalyst Bio. So gentlemen, thank you so much for joining us this morning.

Grant Blouse
Catalyst Biosciences, Inc. - SVP of Translational Research

Thank you.

Cedric Francois
Apellis Pharmaceuticals, Inc. - Co-Founder, President, CEO & Director

[It's great.]

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot